Related Experiment Video
Updated: Oct 8, 2025

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
Published on: February 9, 2021
Effect of obesity and metabolic health on urolithiasis: A nationwide population-based study
Changil Choi1, Jong Keun Kim1, Kyungdo Han2
1Department of Urology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
Purpose:
To investigate the risk of symptomatic urolithiasis requiring surgical treatment according to obesity and metabolic health status using a nationwide dataset of the Korean population.
Materials And Methods:
Of the 5,300,646 persons who underwent health examinations between the year 2009 and 2016, within one year after the health examination, 35,137 patients who underwent surgical treatment for urolithiasis were enrolled. Participants were classified as "obese" or "non-obese" using a body mass index (BMI) cutoff of 25 kg/m². People who developed ≥1 metabolic disease component in the index year were considered "metabolically unhealthy", while those with none were considered "metabolically healthy".
Results:
Out of 34,330 participants excluding 843 missing, 16,509 (48.1%), 4,320 (12.6%), 6,456 (18.8%), and 7,045 (20.5%) subjects were classified into the metabolically healthy non-obese (MHNO), metabolically unhealthy non-obese (MUNO), metabolically healthy obese (MHO), and metabolically unhealthy obese (MUO) group, respectively. Mean BMI was 22.1±1.9 kg/m², 22.9±1.6 kg/m², 26.9±1.8 kg/m², and 27.9±2.4 kg/m² respectively. After adjusting the age and sex, the subjects in the MUNO group had an HR (95% CI) of 1.192 (1.120-1.268), those in the MHO group, 1.242 (1.183-1.305), and those in the MUO group, 1.341 (1.278-1.407) for either extracorporeal shockwave lithotripsy or surgery, compared to those in the MHNO group.
Conclusions:
Metabolically healthy, obese individuals have a higher risk of developing symptomatic urolithiasis than non-obese, unhealthy, but have a lower risk than obese, unhealthy. It suggests that metabolic health and obesity have collaborative effects, independently affecting the development of symptomatic urinary stone diseases.
Related Concept Videos
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi I: Introduction
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

